Arcellx (ACLX)

Executive Summary

Arcellx is a clinical-stage biotechnology company pioneering next-generation cell therapies for cancer and autoimmune diseases. Its lead program, anito-cel (formerly CART-ddBCMA), is a novel BCMA-targeting CAR-T therapy designed with a synthetic binding domain (D-Domain) to improve durability and reduce resistance. In multiple myeloma, anito-cel has shown promising early efficacy and a favorable safety profile, with potential best-in-class characteristics. The company is also exploring anito-cel in autoimmune indications, including myasthenia gravis, where a Phase 1 trial is recruiting. Additionally, Arcellx is developing SPRX002, an ARC-T cell therapy for acute myeloid leukemia and myelodysplastic syndromes. With a strong balance sheet and a validated platform, Arcellx is well-positioned to advance its pipeline. Key upcoming milestones include data readouts from its ongoing trials, which could drive significant value.

Upcoming Catalysts (preview)

• H2 2026Anito-cel Phase 1 data update in relapsed/refractory multiple myeloma85% success
• 2027Initiation of pivotal trial for anito-cel in multiple myeloma70% success
• 2026Phase 1 data readout for anito-cel in autoimmune disease (myasthenia gravis)60% success